Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $30.7 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 1088.74% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 1088.74%. This contributed to the annual value of $30.7 million for FY2025, which is 1088.74% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Accumulated Expenses stood at $30.7 million for Q3 2025, which was down 1088.74% from $27.8 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Accumulated Expenses high stood at $36.7 million for Q2 2023, and its period low was $15.2 million during Q4 2022.
  • For the 5-year period, Enanta Pharmaceuticals' Accumulated Expenses averaged around $26.6 million, with its median value being $27.8 million (2025).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Accumulated Expenses crashed by 4295.33% in 2022, and later soared by 14079.67% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses (Quarter) stood at $26.6 million in 2021, then plummeted by 42.95% to $15.2 million in 2022, then surged by 140.8% to $36.5 million in 2023, then fell by 10.32% to $32.7 million in 2024, then fell by 6.21% to $30.7 million in 2025.
  • Its Accumulated Expenses stands at $30.7 million for Q3 2025, versus $27.8 million for Q2 2025 and $30.7 million for Q1 2025.